Incidence of bone fracture in Japanese patients receiving long-term hormone therapy for prostate cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16098-e16098
Author(s):  
Hiroji Uemura ◽  
Hideo Fusayasu ◽  
Shinji Ohtake ◽  
Narihiko Hayashi ◽  
Yumiko Yokomizo ◽  
...  

e16098 Background: For patients with advanced prostate cancer, long-term treatment of androgen deprivation has been conventionally performed. Among the adverse events such as hormonal therapy, bone fracture due to osteoporosis or metastatsis is one of indispensable events. We assessed the frequency of bone fractures in Japanese patients received hormonal therapy. Methods: Between 2000 and 2010, 1,108 Japanese patients were treated with hormonal therapy including GnRH agonist plus anti-androgens or GnRH agonist alone at Yokohama City University Hospital. Of those patients, 48 patients (4.3%) had bone fractures during their treatment. In this retrospective study, we examined the association of bone fracture with the long-term hormonal therapy by investigating the duration of hormonal therapy, fracture sites, and the occurrence of fracture in castration resistant prostate cancer (CRPC) patients. Results: The median age of the patients with fracture was 77 (60-85) years; the median duration from the start of hormonal therapy to fracture was 29.4 (5.4-110.4) months. Eight patients with CRPC had pathological fractures at bone metastases. With respect of fracture sites, 22 patients (46%) had spinal fractures and 10 patients (21%) had fracture of lower legs. Of 8 CRPC patients, 7 patients had spinal fracture after long-term hormonal therapy (median: 38.6 months, range: 15.7-99.1 months). Conclusions: Japanese patients with prostate cancer treated with hormonal therapy have lower risk for bone fracture compared with those in western countries and USA, and interestingly, it is recognized that vertebral body is vulnerable to fracture in Japanese, especially in CRPC patients treated for long-term hormonal therapy. Because bone fracture in patients with prostate cancer endanger their prognosis, the bone management how to prevent bone fracture is very important during hormonal therapy. For the purpose of it, more detailed analysis in this retrospective study should be required.

2010 ◽  
Vol 162 (1) ◽  
pp. 177-181 ◽  
Author(s):  
Talia Eldar-Geva ◽  
Gad Liberty ◽  
Boris Chertin ◽  
Alon Fridmans ◽  
Amicur Farkas ◽  
...  

ObjectivesMedical castration with long-acting GnRH-agonist (GnRHa) is a well-established treatment for metastatic prostate cancer. Our aim was to explore the relationships between FSH, inhibin B, anti-Mullerian hormone (AMH), and testosterone during treatment with an implant releasing GnRHa.DesignAnalysis of hormone levels in frozen serum samples.MethodsTen patients aged 77±7 (means±s.e.m.) years with prostate cancer were treated with the GnRHa histrelin for at least a year. Two weeks prior to insertion and for 3–4 months following removal the patients were treated with the antiandrogen flutamide. Serum inhibin B, FSH, testosterone, and AMH levels were measured retrospectively.ResultsFSH, inhibin B, and testosterone increased during antiandrogen administration and levels fell after implant insertion. Four weeks post insertion, FSH gradually increased while inhibin B and testosterone remained fully suppressed. AMH levels did not change during antiandrogen treatment, but increased following implant insertion and remained elevated for the duration of implant use. Following removal, FSH and testosterone increased, inhibin B remained low, while AMH decreased.ConclusionsThe secondary increase in FSH following initial suppression with the implant is probably related to impaired inhibin B secretion. The lack of inhibin B response to the secondary increase in FSH suggests that long-term exposure of Sertoli-cells to GnRHa impairs their function. This effect appears to be selective since unlike inhibin B, AMH increased. In the absence of testosterone, FSH has a role in AMH regulation.


BMC Urology ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Takashi Kawahara ◽  
Shusei Fusayasu ◽  
Koji Izumi ◽  
Yumiko Yokomizo ◽  
Hiroki Ito ◽  
...  

2018 ◽  
Vol 24 (3) ◽  
pp. S86-S87
Author(s):  
Federica Barzaghi ◽  
Laura Amaya Hernandez ◽  
Sung-Yun Pai ◽  
Benedicte Neven ◽  
Franco Locatelli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document